Clinical Trial

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 11, 2022 (before its estimated December 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This randomized, active-controlled, multicenter, open-label, Phase II study is designed to evaluate the efficacy and safety of ensatinib compared with Platinum-Based Chemotherapy as adjuvant treatment in ALK fusion positive II-IIIA stage non-small cell lung cancer after surgical resection
Trial Details
NCT Number NCT05186506
Lead Sponsor Sichuan University
Collaborators: Betta Pharmaceuticals Co., Ltd.
Conditions ALK Fusion Protein Expression, Adjuvant Therapy, Non-Small Cell Lung Cancer
Enrollment 152 participants
Start Date 2022-01-01
Primary Completion 2025-12-15 (estimated)
Study Completion 2028-12-20 (estimated)
Updated on ClinicalTrials.gov 2022-01-11